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Abstract
Background Frailty is common in patients with chronic heart failure (CHF) and is associated with poor outcomes. The 
natural history of frail patients with CHF is unknown.
Methods Frailty was assessed using the clinical frailty scale (CFS) in 467 consecutive patients with CHF (67% male, median 
age 76 years, median NT-proBNP 1156 ng/L) attending a routine follow-up visit. Those with CFS > 4 were classified as frail. 
We investigated the relation between frailty and treatments, hospitalisation and death in patients with CHF.
Results 206 patients (44%) were frail. Of 291 patients with HF with reduced ejection fraction (HeFREF), those who were 
frail (N = 117; 40%) were less likely to receive optimal treatment, with many not receiving a renin–angiotensin–aldosterone 
system inhibitor (frail: 25% vs. non-frail: 4%), a beta-blocker (16% vs. 8%) or a mineralocorticoid receptor antagonist (50% 
vs 41%). By 1 year, there were 56 deaths and 322 hospitalisations, of which 25 (45%) and 198 (61%), respectively, were due 
to non-cardiovascular (non-CV) causes. Most deaths (N = 46, 82%) and hospitalisations (N = 215, 67%) occurred in frail 
patients. Amongst frail patients, 43% of deaths and 64% of hospitalisations were for non-CV causes; 58% of cardiovascular 
(CV) deaths were due to advancing HF. Among non-frail patients, 50% of deaths and 57% of hospitalisations were for non-
CV causes; all CV deaths were due to advancing HF.
Conclusion Frailty in patients with HeFREF is associated with sub-optimal medical treatment. Frail patients are more likely 
to die or be admitted to hospital, but whether frail or not, many events are non-CV.
Supplementary Information The online version contains 
supplementary material available at https ://doi.org/10.1007/s0039 
2-020-01792 -w.
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Introduction
Up to 50% of patients with chronic heart failure (CHF) are 
frail, and frailty is associated with an increased risk of mor-
bidity and mortality [1, 2]. Frailty is a “multidimensional 
dynamic state, independent of age that makes the individual 
with CHF more vulnerable to the effect of stressors” [2]. 
The relation between CHF and frailty is complex: patients 
with CHF are up to six times more likely to be frail than 
those without CHF and frail individuals have a higher risk 
of developing CHF [3].
Clinical trials suggest that the vast majority of deaths 
in patients with CHF are cardiovascular, either due to pro-
gression of the underlying disease, or sudden, secondary to 
a fatal myocardial infarction or arrhythmias [4]. However, 
patients enrolled in clinical trials are poorly representative of 
those seen in routine clinical practice, who are usually older, 
with more comorbidities, and more likely to be frail [5]. The 
natural history of frail patients with CHF is unknown. A 
better understanding of their current management and of the 
reasons for their hospitalisations or death might help tailor 
future therapeutic strategies and enable more appropriate use 
of healthcare resources.
We therefore evaluated the causes of death and hospitali-
sations in ambulatory patients with CHF and their relation 
to frailty. We also assessed the association between frailty 
and rates of non-prescription of evidence-based therapies 




Between September 2016 and March 2017, we enrolled 
consecutive ambulatory patients with CHF who attended a 
community CHF clinic for a routine follow-up appointment. 
All patients had a pre-existing (> 1 year) clinical diagno-
sis of CHF, confirmed by either evidence of left ventricular 
systolic dysfunction on echocardiography (left ventricular 
ejection fraction (LVEF) < 40% or at least moderate left ven-
tricular systolic dysfunction by visual inspection if LVEF 
was not calculated), defined as heart failure with reduced 
ejection fraction, HeFREF; or normal left ventricular sys-
tolic function (LVEF >/= 40%) and N-terminal pro-B-type 
natriuretic peptide (NTproBNP) > 400 ng/L, defined as heart 
failure with normal ejection fraction, HeFNEF [6].
During the visit, all patients had a full medical history 
and medication review, physical examination, blood tests 
(full blood count, urea and electrolytes and NT-proBNP), 
an electrocardiogram and a consultation with a heart failure 
specialist.
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Frailty assessment
During the same clinical visit, all patients were assessed for 
frailty using the Clinical Frailty Scale (CFS) by the same 
researcher (SS) (Online resource 1). CFS measures between 
1 (very fit) and 9 (terminally ill). Subjects are scored accord-
ing to their functional capacity, level of dependence and 
co-morbidities. For example, a patient with uncontrolled 
symptoms who is not frankly dependent is classified as vul-
nerable and scores 4 on the CFS; while an individual with 
limited dependence on others for instrumental activities of 
daily living including finances, transportation, heavy house-
work and medications will be classified as mildly frail and 
scores 5 on the CFS. Subjects with a CFS > 4 are classi-
fied as frail (Online resource 1) [7]. We stratified patients 
into five categories: non-frail (CFS 1–3), pre-frail (CFS 4), 
mildly frail (CFS 5), moderately frail (CFS 6) and severely 
frail (CFS ≥ 7). We chose CFS to evaluate frailty as it is a 
simple tool and has similar classification performance and 
prognostic value as alternative assessment tools taking much 
longer to perform [7, 8].
Co‑morbidities
Co-morbidities were measured using the Charlson co-
morbidity index/score [9]. Hypertension was defined as 
systolic blood pressure ≥ 140 mmHg, diastolic blood pres-
sure ≥ 90 mmHg or a previous clinical diagnosis [10]. Cur-
rent haemoglobin (Hb) levels were used to define anaemia 
(Hb < 13.0 g/dL in men and < 12.0 g/dL in women) [11]. 
Diabetes mellitus was defined according to the guideline 
from Diabetes UK [12]. Patients consented to the use of 
electronic medical records to identify their previous medi-
cal history.
Follow‑up
All patients were followed up for a minimum of 1 year. 
Patients were followed up until 1st of August 2018. Our 
hospital is the only one in the region offering acute medical 
services. For the purpose of this study, we studied the pri-
mary cause of hospitalisations and death. Hospitalisations 
refer to non-elective admissions to hospital which require 
overnight stay.
Hospitalisation was ascertained using the hospital cod-
ing system, electronic medical records and discharge letters. 
Cardiovascular (CV) hospitalisations included hospitalisa-
tions secondary to decompensated CHF, acute coronary 
syndrome (ACS), arrhythmias, cerebrovascular accidents 
(CVA) and peripheral vascular disease (PVD). Other hospi-
talisations were regarded as non-cardiovascular (non-CV), 
including those related to acute kidney injury (AKI), falls, 
or infections.
Death adjudication followed a standard procedure. For 
those who died in hospital, the hospital notes were reviewed 
and cause of death was adjudicated. For those who died out-
side hospital, the patient’s general practitioner was contacted to 
obtain the cause of death recorded on death certificates. If this 
was unsuccessful, the cause of death was adjudicated based on 
previous medical records, recent hospitalisations and medical 
encounters. A detailed description of the adjudication process 
can be found in Online resource 2.
CV deaths included presumed sudden cardiac deaths or 
those caused by myocardial infarction (MI), terminal HF or 
CVA. Other deaths were regarded as non-CV, including those 
due to infection, malignancy or other comorbidities.
Statistical analysis
Continuous data are expressed as a median (25th–75th cen-
tiles) and categorical data are expressed as %. Independent t 
tests and Mann–Whitney U tests were used to compare two 
continuous variables for normally and non-normally distrib-
uted data, respectively. The Chi-squared test was used to com-
pare proportions between groups.
We studied the prescribing pattern of major classes of CHF 
medications (according to the European Society of Cardiology 
Guidelines) [8] in patients with HeFREF stratified by degree 
of frailty and correlated that with outcome. A detailed descrip-
tion of optimal doses of medications for patients with HeFREF 
is shown in online resource 3. Univariable and multivariable 
analyses with Cox proportional hazard regression were per-
formed to determine the prognostic value of frailty. Bar charts 
are used to illustrate the proportion of HF vs. CV non-HF 
vs. non-CV deaths and hospitalisations in frail vs. non-frail 
patients. We also studied the detailed causes of CV and non-
CV deaths and hospitalisations. We compared the causes of 
death and hospitalisations in patients stratified according to 
HF phenotype (HeFREF vs. HeFNEF), sex (male vs. female) 
and degree of frailty by CFS (non-frail, pre-frail, mildly frail, 
moderately frail and severely frail).
All statistical analyses were performed using SPSS 26 
(SPSS INc.,Chicago, IL, USA) and the Stata (14th Ver-
sion, StataCorp, TX, USA) statistical computer package. A 
two-tailed P value of < 0.05 was considered significant in all 
analyses.
The study conformed to the principles outlined in the Dec-
laration of Helsinki and was approved by relevant ethical bod-
ies. All subjects gave their written informed consent for their 
data to be used for research.




A total of 467 consecutive ambulatory patients with CHF 
was studied. Table 1 shows the baseline characteristics of 
the study population. The majority of patients were male and 
elderly; most patients had HeFREF (62%) with median NT-
proBNP of 1156 (496–2463) ng/L; around 20% had severe 
symptoms [New York Heart Association (NYHA) class III/
IV]. Almost half (44%) of the patients were frail.
Compared to patients who were not frail, those who were 
frail were older, more likely to be female and more likely 
to have HeFNEF. They had more comorbidities and worse 
renal function with lower body mass index (BMI) and hae-
moglobin. They also had more severe symptoms and higher 
NT-proBNP (Table 1).
Medication in patients with HeFREF and degree 
of frailty
Figure 1a shows the three major classes of CHF medica-
tions prescribed in patients with HeFREF stratified accord-
ing to the degree of frailty. Compared to non-frail patients, 
frail patients were less likely to be prescribed ACEi/ARB, 
beta-blockers and MRA (Fig. 1a-b). Those who did receive 
treatment were more likely to receive sub-optimal doses 
(Fig. 1a). As frailty worsened, the likelihood of receiving 
sub-optimal doses increased.
Frailty is an independent predictor of poor outcome
Worsening frailty, as determined by increasing CFS score, 
was associated with increased risk of all-cause mortality 
and combined all-cause mortality/all-cause hospitalisation at 
1 year in both univariable and multivariable Cox regression 
analyses after adjustment of age, BMI, NYHA class, Charl-
son score, log[NTproBNP], haemoglobin and estimated glo-
merular filtration rate (Online resource 4a and 4b).
Cause of death
By 1-year follow-up, 56 (12%) patients had died, represent-
ing 22% (N = 46) of the frail patients and 4% (N = 10) of 
the non-frail (Fig. 2). In frail patients who died, the cause 
was non-CV in 43%, compared with 50% amongst non-frail 
patients (P = 0.71). Regardless of frailty status, infection was 
the commonest cause of non-CV deaths, while advancing 
HF was the commonest cause of CV death. The primary 
cause of death was similar between patients with different 
HF phenotypes and sexes (Online resource 5a). The propor-
tion of non-CV deaths increased with increasing severity of 
frailty (Fig. 3).
Cause of hospitalisation
By 1-year follow-up, there were 322 non-elective hospitali-
sations; 215 events occurred in 96 (47%) frail patients and 
107 events in 54 (21%) non-frail patients (Fig. 4). In frail 
patients, 64% of hospitalisations were due to non-CV causes 
compared with 57% in non-frail patients (P = 0.25). Regard-
less of frailty status, decompensated HF was the commonest 
cause of CV hospitalisations. Of non-CV hospitalisations, 
falls were more common in frail patients, particularly in 
those with HeFNEF and in female patients, while admis-
sions related to comorbidities were more common in non-
frail patients (Fig. 4 and Online resource 5b). The proportion 
of non-CV hospitalisations increased with increasing sever-
ity of frailty (Fig. 3).
Recurrent hospitalisations
The average numbers of hospitalisations per patient per 
365 days of follow-up in frail and non-frail patients are 1.0 
and 0.4, respectively (P < 0.001). Of patients who were frail 
(N = 206), 96 experienced hospitalisation, of whom many 
had recurrent hospitalisations: 2nd hospitalisations N = 59; 
3rd hospitalisations N = 35 and ≥ 4 hospitalisations N = 13 
(Fig. 5). The majority of recurrent hospitalisations were due 
to non-CV causes (Fig. 5). The causes of recurrent hospi-
talisations in HeFREF and HeFNEF patients are shown in 
Online resource 6.
Discussion
Our study is the first to examine the relation between frailty 
and causes of death, first and recurrent hospitalisations in a 
well-characterised cohort of ambulatory patients with CHF. 
We found that during the first year of follow-up, compared 
to non-frail individuals, frail patients experienced a far 
higher rate of death and hospitalisations, a large proportion 
of which were for non-CV causes. The proportion of events 
due to non-CV reasons was high and similar in frail and 
non-frail patients when frailty was treated as a categorical 
variable, but as the frailty status of a patient worsened, the 
proportion of non-CV deaths and hospitalisations increased. 
We also found that frail patients with HeFREF were less 
likely to receive (or receive optimal doses of) guideline-
recommended CHF therapy.
Before the era of ACE inhibitors, it was estimated 
that 90% of the total deaths in patients with CHF were 
from CV causes [14, 15]. In contrast, we have found that 
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Table 1  Baseline characteristics of patients with CHF by frailty status according to the CFS
HF heart failure, HR heart rate, BP blood pressure, NYHA new York heart association, HeFREF heart failure with reduced ejection frac-
tion, HeFNEF heart failure with normal ejection fraction, BMI body mass index, MI = myocardial infarction, PVD peripheral vascular dis-
ease, HTN hypertension, CVA/TIA cerebrovascular accident/ transient ischaemic attack, COPD chronic obstructive pulmonary disease, BB 
beta-blocker, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, MRA mineralocorticoid receptor antagonist, 
NTproBNP = N-terminal pro-B-type natriuretic peptide, Hb = haemoglobin, Na = sodium, K = potassium, eGFR = estimated glomerular filtration 
rate
Entire cohort (N = 467) CFS P (Frail vs. 
non-frail)
Non-frail (CFS ≤ 4) 
(N = 261)
Frail (CFS > 4) (N = 206)
Demographics
Age, years 76 (69–82) 72 (65–79) 80 (74–85)  < 0.001
Sex (male), % 67 72 60 0.005
HR (bpm) 70 (60–80) 70 (61–80) 70 (60–81) 0.70
BP systolic (mmHg) 139 (126–162) 140 (126–158) 137 (126–167) 0.55
BP diastolic (mmHg) 75 (66–83) 75 (67–83) 74 (65–83) 0.20
NYHA III/IV, % 22 10 38  < 0.001
HeFREF, % 62 67 57 0.03
HeFNEF, % 38 33 43
Height (m) 1.68 (1.61–1.75) 1.70 (1.64–1.76) 1.66 (1.59–1.73)  < 0.001
Weight (kg) 83 (69–99) 86 (74–102) 77 (65–94)  < 0.001
BMI (kg/m2) 29.0 (25.0–33.2) 29.3 (26.0–34.2) 28.4 (24.2–32.4) 0.01
Comorbidities
 Charlson score 8 (6–10) 7 (5–9) 9 (8–11)  < 0.001
 MI, % 42 43 42 0.80
 PVD, % 15 12 19 0.03
 HTN, % 67 64 70 0.17
 CVA/TIA, % 15 10 22  < 0.001
 AF, % 46 41 52 0.01
 Diabetes, % 35 31 39 0.08
 Dementia, % 10 2 21  < 0.001
 COPD, % 30 24 37 0.002
 Depression, % 20 15 27 0.001
 Anaemia, % 47 36 60  < 0.001
 Recurrent falls, % 37 18 61  < 0.001
Medications
 BB, % 84 88 79 0.01
 ACEi/ARB, % 83 90 74  < 0.001
 MRA, % 46 49 41 0.08
 Digoxin, % 21 22 21 0.80
 Loop diuretic, % 74 69 82 0.001
 Statins, % 62 65 59 0.18
 Pacemakers/devices, % 18 12 26  < 0.001
Blood tests
 NTproBNP (ng/L) 1156 (496–2463) 877 (372–1717) 1622 (784–3296)  < 0.001
 Hb (g/L) 131 (118–142) 135 (124–145) 123 (114–136)  < 0.001
 Na (mmol/L) 137 (135–138) 137 (135–139) 136 (134–138) 0.04
 K (mmol/L) 4.4 (4.2–4.7) 4.5 (4.2–4.7) 4.4 (4.1–4.7) 0.09
 eGFR (mL/min per 1.73  m2) 55 (40–73) 60 (45–76) 50 (33–67)  < 0.001
 Creatinine (µmol/L) 103 (84–131) 99 (83–123) 110 (88–141) 0.001
1 year outcomes
 All-cause deaths, % 12 4 22  < 0.001
  ≥ 1 hospitalisations, % 32 21 47  < 0.001
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approximately half of all deaths were due to non-CV causes. 
Our findings are similar to those from a Spanish cohort 
study which explored the cause of death in 1876 ambula-
tory patients with CHF (75% male, median age 66 years, 
LVEF < 50%) between 2002 and 2018 [16]. During a median 
follow-up of 4.2 years, there were 935 deaths, of which 40% 
were non-CV and 60% were CV. The authors also noticed 
a progressive increase in the rate of non-CV death over 
time, representing more than 50% of total deaths from 2015 
onwards.
There has been a remarkable shift in the causes of death 
in CHF populations over the past two decades. In par-
ticular, there has been a significant reduction in sudden 
death and a concomitant increase in non-CV deaths [17]. 
There are several possible explanations. First, as a result 
of improvement in the management of conditions leading 
to CHF, such as coronary artery disease and hyperten-
sion, and major advances in treatment for HeFREF, an 
increasing proportion of patients with CHF is frail and 
elderly. Almost half (44%) of the patients we studied were 
frail. Multi-morbidity is extremely common in patients 
with CHF. In the UK, 79% of patients with CHF have 
three or more comorbidities [18]. Non-CV diseases, such 
as malignancies, chronic kidney disease, cognitive decline 
and depression, are very common amongst patients with 
CHF [18]. Second, as the population ages, the propor-
tion of patients with CHF who have HeFNEF increases, 
these patients have a particularly high burden of comor-
bidities and are thus at high risk of non-CV deaths and 
hospitalisations.
Fig. 1  a: Major classes of 
CHF medications prescribed in 
patients with HeFREF accord-
ing to frailty categories (upper 
left: Beta-blockers (BB); upper 
right: ACEi/ARB; lower left: 
MRA). The numbers within 
bars represent the percentage 
of patients on different dose 
ranges of CHF medications in 
each frailty category. b: Number 
of HF medications prescribed 
for patients with HeFREF 
according to frailty status. *HF 
medications refer to ACEi/
ARB, beta-blockers and MRA
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CHF is a cardiogeriatric syndrome, but frail elderly 
patients are under-represented in the vast majority of clini-
cal trials in CHF [19]. Part of the reason are the efforts of 
investigators to make sure that any treatment effects are 
not swamped by the effects of comorbidities; and partly 
because of the inability (perceived or otherwise) of older, 
frailer patients to cope with frequent study-related visits and 
procedures. To take as an example, the recent PARADIGM-
HF trial [20]: applying the inclusion and exclusion crite-
ria to the population we report here, 83% of frail patients 
would have been excluded compared to 65% of non-frail 
patients (p < 0.001) (Online resource 7). The consequence 
is that it can be difficult to ascertain what the effect of spe-
cific treatments might be in older, frailer patients. Very few 
studies have evaluated treatments specifically in elderly 
patients. Examples include the SENIORS trial, [21] which 
studied the effect of nebivolol on outcomes in patients with 
CHF > 70 years; and CIBIS-ELD trial, [22] which com-
pared the tolerance of bisoprolol and carvedilol in patients 
with CHF > 65 years. In recent trials, such as DAPA-HF 
and PARADIGM-HF, only a minority of patients enrolled 
were > 75 years of age (24% and 19%, respectively) [20, 23]. 
However, there was no evidence of lesser benefit from sacu-
bitril/valsartan or dapaglifozin in older patients according to 
these trials [20, 23].
The ESC/HFA guidelines recommend evidence-based 
pharmacotherapy for HeFREF patients irrespective of age. 
[13] However, we found that a large proportion of frail 
patients were prescribed sub-optimal CHF therapy. The 
worse the frailty status, the less likely it was for patients 
to receive optimal CHF therapy. Reasons include the pos-
sibility of more side effects or greater intolerance to medi-
cations in frailer patients; or physician inertia in initiating 
and up-titrating guideline-recommended medications in 
older patients. The presence of comorbidity, such as renal 
impairment, is increasingly common as the degree of frailty 
increases. Loop diuretics, on the other hand, are commonly 
used in frail patients, which might reflect attempts to treat 
severe symptoms and signs due to congestion [24].
The prevalence of frailty will increase as the popula-
tion ages. The management of frail patients with CHF will 
become a significant medical challenge. We have shown 
that although frail patients are sub-optimally treated for HF, 
Fig. 2  Cause of death at 1 year in frail vs. non-frail patients
Fig. 3  HF vs. CV non-HF vs non-CV deaths (left panel) and hospitalisations (right panel) at 1 year in frail vs. non-frail patients according to 
degree of frailty
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they are less likely to die of HF as frailty increases. Aggres-
sive HF treatment is perhaps less and less important with 
increasing frailty; interventions to address frailty rather than 
to address HF are what is needed for these patients. Holis-
tic care using a patient-centred approach is required. Com-
mon issues, such as malnutrition [25], cognitive decline, 
reduced mobility and depression [26], should be assessed 
and addressed as early as possible. More emphasis should be 
put on exploring what is important to the patient and pallia-
tive care should be considered according to the individual’s 
wishes [27].
Study limitations
This study has some limitations. First, the study was con-
ducted in a single centre in the UK with limited sample size, 
and thus external validation of our results from other popula-
tions with different healthcare and social systems is needed.
Second, we have only studied one of the most commonly 
used frailty tools. A large number of frailty screening and 
assessment tools have been proposed and identified patients 
at risk of adverse outcome in other clinical scenarios [28]. 
However, we have previously shown that CFS identifies 
frailty [1] and provides comparable prognostic information 
to assessment tools taking longer to perform [8].
We have clear in-house guidance to adjudicate events 
in a coherent and objective manner, but we recognise that 
accuracy of adjudication might have been sub-optimal. 
Patients with CHF are mostly elderly with multiple comor-
bidities, and some events, such as pulmonary embolism or 
infections, might have been missed as a cause of death [29]. 
Whilst autopsy is the gold standard for determining cause 
Fig. 4  Cause of hospitalisations 
at 1 year in frail vs. non-frail 
patients
Fig. 5  Cause of recurrent hos-
pitalisations at 1 year in frail vs. 
non-frail patients with CHF
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of death, they are rarely performed, and may not provide 
conclusive evidence [30]. In our department, event adju-
dication was performed by experienced physicians trained 
for the purpose. In cases where the cause of hospitalisation 
was uncertain, to ensure the accuracy of the adjudication 
process, the research medical team reviewed all medical 
entries, blood tests and radiological evidences available dur-
ing that hospital admission to determine the primary cause 
of hospitalisation.
Although we collected data regarding medication use in 
our cohort, we did not study the reasons for under-prescrip-
tions and missed/ failed up-titration of anti-HF medications. 
Further studies are needed to identify factors associated with 
under prescription of medication in patients with HeFREF, 
with a particular focus on the role of frailty in drug intol-
erance and non-adherence, so that targeted interventions 
can be developed to improve prognosis of this high-risk 
population.
Conclusion
Frailty in patients with HeFREF is associated with sub-
optimal medical treatment. Frail patients are more likely to 
die or be admitted to hospital, but whether frail or not, many 
events are non-CV, suggesting that non-HF interventions 
might be important. A holistic and patient-centred approach 
is needed to address the various healthcare needs of patients 
with CHF, especially in those living with frailty.
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